NCT03019549View on ClinicalTrials.gov

A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

January 12, 2017

Primary Completion Date

May 22, 2017

Study Completion Date

May 22, 2017

Conditions

Healthy

Interventions

DRUG

Lanabecestat

Administered orally

DRUG

Rosuvastatin

Administered orally

Trial Locations (1)

32117

Covance Clinical Research Inc, Daytona Beach

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT03019549 - A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin | Biotech Hunter | Biotech Hunter